Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab-Reference-Cited by-同舟云学术

Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab

Published:2023-04-04 Issue: Volume:34 Page:191-194
ISSN:1998-3662
Container-title:Indian Journal of Nephrology
language:en
Short-container-title:IJN

Author:

Chaudhary Satish¹,Sharma Reetesh¹,Gupta Saumya¹,Paikra Sita¹,Gupta Mohit¹,Upadhyay Bal K.¹,Sharma Alok²,Sethia Rajiv K.¹

Affiliation:

1. Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India

2. Nephrology and Kidney Transplant Medicine, Dr. Lalpathlabs National Reference Laboratories, New Delhi, India

Abstract

Posttransplant thrombotic microangiopathy (PT-TMA) can be caused by calcineurin inhibitors (CNIs), ischemic injury, infections, or antibody-mediated rejection (ABMR). Delayed recognition can result in allograft loss. We describe the first reported case of successful reversal of refractory PT-TMA with eculizumab in India. It highlights the importance of prompt diagnosis and benefit from an early initiation of eculizumab therapy in refractory cases.

Publisher

Scientific Scholar

Reference16 articles.

1. De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy;Schwimmer;Am J Kidney Dis,2003

2. Thrombotic microangiopathy after renal transplantation in the United States;Reynolds;Am J Kidney Dis,2003

3. Calcineurin inhibitor nephrotoxicity;Naesens;Clin J Am Soc Nephrol,2009

4. Eculizumab and belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: A case report;Dedhia;Transplant Proc,2017

5. Efficacy of eculizumab therapy for atypical hemolytic uremic syndrome recurrence and antibody-mediated rejection progress after renal transplantation with preformed donor-specific antibodies: Case report;Yamamoto;Transplant Proc,2017